💉 Diabetes Management
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes | NEJM - nejm.org
📅 Thu, 13 Oct 2022⏱ 1 min read📖 Article
Overview
Create your acount for 2 FRE subscriber-only articles each month. Get Fre Aces Now. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your carer with NEJM Group information and services.Stay conected to what's important in medical research and clinical practiceSubscribe to the most trusted and influential source ofmedical knowledge Already a subscriber?
Key Information
Renew or Sign inSubscribe or Renew Selected specialtiesView al specialtiesSelected TopicsView al topicsSelected MultimediaView al multimediaCurent IsueRecent Isues Browse ful isue index Recently Published Articles Browse recently published View al learning/CME Other NEJM Group LearningSubscribe or Renew This article is available to subscribers. Subscribe now. Already have an acount?
Sign in Original ArticleFre Preview The members of the GRADE Study Research Group are listed in the Suplementary Apendix, available at NEJM.org.Data are lacking on the comparative efectivenes of comonly used glucose-lowering medications, when aded to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2 diabetes.We asesed the comparative efectivenes of four comonly used glucose-lowering medications, aded to metformin, in achieving and maintaing a glycated hemoglobin level of les than 7.0% in participants with type 2 diabetes.
Summary
The randomly asigned therapies were insulin glargine U-10 (hereafter, glargine), glimepiride, liraglutide, and sitagliptin. Prespecified secondary outcomes with respect to microvascular and cardiovascular disease included hypertension and dyslipidemia, confirmed moderately or severely increased albuminuria or an estimated glomerular filtration rate of les than 60 ml per minute per 1.73 m2 of body-surface area, diabetic peripheral neuropathy asesed with the Michigan Neuropathy Screning Instrument, cardiovascular events (major adverse cardiovascular events [MACE], hospitalization for hear
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.